Nemaura Med Inc Stock Price, News & Analysis

Nemaura Medical, Inc. (NASDAQ: NMRD) announced that CEO Dr. Faz Chowdhury will deliver a corporate overview at the Bernstein 2nd Annual CGM Disruptors Conference on November 18, 2022, at 10:30 AM ET. The company specializes in non-invasive wearable diagnostic devices, including the sugarBEAT® continuous glucose monitor, which is CE-mark approved and aimed at helping diabetes management. Nemaura is actively working on its Premarket Approval Application for sugarBEAT® with the U.S. FDA and has launched proBEAT™ in the U.S. as part of its BEAT®diabetes program.

Nemaura Medical, Inc. (NASDAQ:NMRD) will be featured in an interview on The RedChip Money Report® on Bloomberg TV on November 5, 2022, at 7 p.m. ET. The company is known for its noninvasive glucose monitoring devices, including the sugarBEAT®, which aims to assist over 500 million diabetics worldwide. CEO Dr. Faz Chowdhury will discuss the product's potential impact and Nemaura's technology optimization. The company targets the growing diabetes market, forecasting significant growth in wearable health-tech and diagnostic markets.

Nemaura Medical (NASDAQ: NMRD) announced a provisional purchase order from TPMENA for its sugarBEAT® system targeting the Kingdom of Saudi Arabia. The order includes 17,500 devices and 1.7 million sensors, contingent on regulatory approval expected in Q1 2023. The CEO highlighted the significant opportunity in Saudi Arabia due to rising Type II diabetes rates, with 4.1 million cases reported in 2021. Nemaura aims to launch its affordable monitoring solution to help manage diabetes in the region.

Nemaura Medical (NASDAQ: NMRD) announced CEO Dr. Faz Chowdhury will present at the MicroCap Rodeo Windy City Roundup 2022 Conference, taking place from October 12-13, 2022 at the Swissotel Chicago. His presentation is scheduled for 1:00 pm CT on October 12. Dr. Chowdhury will also hold one-on-one meetings with investors registered for the event. Nemaura specializes in non-invasive glucose monitoring technology, including products like sugarBEAT and proBEAT, addressing the growing market for diabetes management.

Nemaura Medical (NASDAQ: NMRD) announced a preliminary agreement with EVERSANA to market its Diabetes Management Solution, BEATdiabetes, across the U.S. and globally. The BEATdiabetes program utilizes Nemaura's noninvasive glucose monitoring technology, proBEAT. Initial pilot trials over the last year showed positive outcomes, indicating potential for sustainable weight loss and improved Type 2 diabetes management. The partnership aims to develop a strategic launch plan targeting self-insured corporate clients and healthcare insurers.

Nemaura Medical, a medical technology firm, announces on September 6, 2022, that CEO Dr. Faz Chowdhury will provide a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference from September 12-14, 2022. The presentation will be available on-demand starting September 12, 2022, at 7:00 a.m. ET for registered attendees. Nemaura specializes in non-invasive wearable diagnostics, including its sugarBEAT® continuous glucose monitor, with a focus on managing diabetes. The company aims to support metabolic health for a large portion of the population.

Nemaura Medical (NMRD) reported its financial results for the quarter ending June 30, 2022. The company received $5 million from a note purchase agreement in May 2022, enhancing its financial position without diluting existing shares. Operating expenses totaled about $1.6 million, and cash reserves decreased to approximately $14.8 million from $17.7 million in the prior quarter. CEO Dr. Faz Chowdhury highlighted advancements in manufacturing and commercialization of their innovative glucose sensor, aiming for growth in revenue as they build inventory and enhance operational capacity.

Nemaura Medical (Nasdaq: NMRD) announced a UK trademark for Meta Score, a digital biomarker for its consumer metabolic health program. This score will combine data from its glucose sensor with user behavior insights, targeting the pre-diabetes and obesity markets, which affect over 87 million Americans. CEO Faz Chowdhury emphasized the importance of this differentiation in the metabolic health sector. The company aims to leverage this trademark as a unique identifier for its lifestyle coaching programs. Trademark applications are also pending in other regions.

Nemaura Medical, Inc. (Nasdaq: NMRD) reported its fiscal year 2022 results ending March 31, 2022, achieving revenue of $503,906 from shipments of its sugarBEAT® continuous glucose monitor to UK licensee MySugarWatch Limited. The company signed a global commercial contract with MySugarWatch DuoPack Limited to combine CGMs with prescription medicines for Type 2 diabetes, targeting over 2 million prescriptions in the top EU markets. Despite consistent R&D expenses at $1.5 million, general and administrative costs increased to $6.17 million, reflecting a growing workforce.